Other Events. As previously disclosed, in April 2026 Vivos Therapeutics, Inc. (the “Company”) received a deficiency notice from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company did not comply with the continued listing requirements of Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), or 5550(b)(3), which require a listed company to maintain a minimum of $2.5 million in stockholders’ equity, a minimum $35 million market value of liste…

Material Modification to Rights of Security Holders. The information set forth in

Other Events. Nasdaq Listing Rule 5550(b)(1) — Stockholders’ Equity As previously disclosed, on April 22, 2026, the Company received a notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company did not satisfy the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), and the Company thereafter submitted a plan to regain compliance. The Prior 8-K i…

Completion of Acquisition or Disposition of Assets. On the Closing Date, the Company completed the acquisition of (i) 3,057,879 shares of common stock of SOD (the “ SOD Shares ”), representing at least eleven percent (11%) of SOD’s fully diluted capital stock immediately after the Closing (as adjusted, in accordance with Section 1.1 of the Agreement, from the 2,907,338 shares reported in the Prior 8-K), and (ii) the Test Interest, in exchange for the issuance to SOD of 12,000 shares of the Co…

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. As previously reported in the Current Report on Form 8-K filed by Vivos Therapeutics, Inc. (the “ Company ”) with the Securities and Exchange Commission (the “ SEC ”) on October 15, 2026 (the “ Prior 8-K ”), on October 14, 2026 the Company entered into a Mutual Stock Purchase and Asset Exchange Agreement (the “Agreement”) with SOD Sciences, Inc., a Nevada corporation (“SOD”), providing for the Company’s acquisition of a minority equity interest in S…

Entry into a Material Definitive Agreement. Mutual Stock Purchase and Asset Exchange Agreement On October 14, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Mutual Stock Purchase and Asset Exchange Agreement (the “Agreement”) with SOD Sciences, Inc., a Florida corporation (“SOD”). SOD owns the ReBalU Protocol, a test/treat/retest platform, the architecture and related patent filings for a pseudohypoxia early-warning test (the “Test”), and has a marketin…

Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On September 29, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Vivos Therapeutics, Inc. (the “Company”) approved the dismissal of Baker Tilly US, LLP (“Baker Tilly”) as the Company’s independent registered public accounting firm, effective as of that date. Baker Tilly, as successor to Moss Adams LLP (“Moss Adams”) in the merger described below, served…

Pursuant to Exchange Agreements dated to be effective as of August 31, 2026, the Company, on September 2, 2026, issued an aggregate of 11,445,080 shares of Common Stock to Streeterville, in twelve separate exchanges as described in

Entry into a Material Definitive Agreement. As previously reported, the Company previously sold and issued to Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”), a Secured Promissory Note with an original issuance date of June 9, 2025 in the original principal amount of $8,225,000 (as amended by that certain Amendment to Secured Promissory Note dated June 5, 2026, and as reinstated and modified by that certain letter agreement dated June 18, 2026, the “Streetervill…

Entry into a Material Definitive Agreement. As previously reported, Vivos Therapeutics, Inc. (the “Company”) previously sold and issued to Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”), a Secured Promissory Note with an original issuance date of June 9, 2025 in the original principal amount of $8,225,000 (as amended by that certain Amendment to Secured Promissory Note dated June 5, 2026, and as reinstated and modified by that certain letter agreement dated Jun…

Effective as of August 31, 2026, the Company agreed to issue an aggregate of 11,445,080 shares of Common Stock to Streeterville, in twelve separate exchanges as described in

Chief Financial Officer — Bradford Amman: Mr. Amman resigned as Chief Financial Officer and Secretary, with an orderly transition plan in place.

Entry into a Material Definitive Agreement. The information set forth under

Unregistered Sales of Equity Securities. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein. Based in part upon the representations of the Investors, the offer and sale of the Units, comprising the Preferred Stock and the Warrants, were made in a private placement transaction exempt from registration in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated there…

Entry into a Material Definitive Agreement. On June 30, 2026, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ PIPE SPA ”) with V-Co Investors 4 LLC, a Wyoming limited liability company (“ V-Co 4 ”) and Bigger Capital Fund, LP (“ Bigger ”). V-Co 4 is a holder of more than 9.99% of the Company’s issued and outstanding common stock, par value $0.0001 per share (the “Common Stock”) and may be deemed an affiliate of the Company…

Entry into a Material Definitive Agreement. On June 10, 2026, Vivos Therapeutics, Inc. (the “Company”) entered into a Collaboration Agreement (the “Collaboration Agreement”) with South Palm Cardiovascular Associates, LLC, a Florida limited liability company (“SPCVA”), pursuant to which the parties agreed to collaborate in the formation and operation of a new management services organization to be known as AIM Florida, LLC (“AIM Florida”). AIM Florida is intended to provide administrative, ope…

Regulation FD Disclosure. On June 10, 2026, the Company issued a press release announcing the Collaboration Agreement and the contemplated collaboration with SPCVA. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…

Other Events. On June 11, 2026, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its intention to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed rights offering, pursuant to which the Company would distribute, as a dividend, transferable subscription rights to its shareholders. Subject to and following the SEC declaring the registration statement effective, the Company intends to distribute the rights as a di…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 5, 2026, the Company received a letter from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, from April 23, 2026 to June 4, 2026, the Company is no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing…

Unregistered Sales of Equity Securities. The information contained above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein. Based in part upon the representations of V-Co 4, the offer and sale of the V-Co 4 Note was made in a private placement transaction exempt for registration in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act and corresponding provisions of state securities or “blue sky” laws. Neither the V-Co 4 Note nor any s…

Entry into a Material Definitive Agreement. Streeterville Capital, LLC Exchange Agreement As previously reported, Vivos Therapeutics, Inc. (the “ Company ”) is a party to a senior secured loan transaction, dated June 9, 2025, with Streeterville Capital, LLC, a Utah limited liability company (“ Streeterville ”), pursuant to which Streeterville previously made a loan to the Company in the form of a Secured Promissory Note (the “ Streeterville Note ”) with an original principal face amount of $8…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained above in Item 1.01, to the extent applicable, is hereby incorporated by reference into this

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 17, 2026, Vivos Therapeutics, Inc. (the “Company”) received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Form 10-K”), did not satisfy the continued listing requirement under Nasd…

Results of Operations and Financial Condition. On April 15, 2026, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities…